University of Trieste, Trieste, Italy.
Infectious Diseases Division, University Hospital of Trieste, Trieste, Italy.
J Dig Dis. 2018 Jun;19(6):322-334. doi: 10.1111/1751-2980.12603. Epub 2018 May 29.
There is increasing evidence of the key role played by altered intestinal microbiota in the pathogenesis of inflammatory bowel disease (IBD). Management strategies involving immune modulation are effective and widely used, but treatment failures and side effects occur. Fecal microbiota transplantation (FMT) provides a novel, perhaps complementary, strategy to restore the normal gut microbiota in patients with IBD. This review summarizes the available efficacy and safety data on the use of FMT in patients with IBD. Several aspects remain to be clarified about the clinical predictors of the response to FMT, its most appropriate route of administration, and the most appropriate quantity and quality of microbiota to be transplanted. Further studies focusing on long-term outcomes and safety are also warranted.
越来越多的证据表明,肠道微生物群的改变在炎症性肠病 (IBD) 的发病机制中起着关键作用。涉及免疫调节的治疗策略是有效的,并且被广泛应用,但仍会出现治疗失败和副作用。粪便微生物群移植 (FMT) 为恢复 IBD 患者的正常肠道微生物群提供了一种新颖的、可能互补的策略。这篇综述总结了 FMT 在 IBD 患者中的应用的现有疗效和安全性数据。关于 FMT 反应的临床预测因素、其最合适的给药途径以及要移植的最适当数量和质量的微生物群,仍有几个方面需要阐明。还需要进一步研究关注长期结果和安全性。